Key Highlights

  • Avitar designed and manufactured diagnostic test products specializing in oral-fluid-based, onsite assay systems for detecting drugs of abuse.
  • Its SEC filing record is extensive but effectively ends around late 2010, with its last reports filed in that period.
  • AVTI traded near $0.00001 per share with a market Capitalization of only a few hundred dollars in the last closing session.
  • The company appears to have ceased current SEC reporting long ago and now exists as a defunct or dormant listing on the OTC market.

Avitar, Inc (OTC:AVTI) was once a functioning medical-diagnostics manufacturer with a real product line, but the ticker now trades at essentially the lowest price a quote can register, a small fraction of a cent, with a Market Value of only a few hundred dollars. The company's SEC reporting trail ran dry more than a decade ago.

Company and Latest Development

Avitar, incorporated in Delaware and historically based in Canton, Massachusetts, designed and manufactured diagnostic test products and medical disposables, specializing in oral-fluid-based, onsite assay systems for detecting drugs of abuse. Its SEC filing record, classified under the surgical-and-medical-instruments industry code, is extensive but effectively ends around late 2010, with its last reports filed in that period.

There is no verifiable recent operational development. The company appears to have ceased current SEC reporting long ago and now exists as a defunct or dormant listing on the OTC market.

What Is Driving Attention Around AVTI?

No confirmed, company-specific catalyst explains current interest in AVTI. The stock is essentially inactive, with trading Volume measured in a handful of shares. When a former operating company stops filing and its shares drift to sub-penny levels, any attention typically reflects screening tools surfacing dormant tickers rather than a genuine Business event.

There is no identifiable public catalyst to point to.

Key Numbers and Company Position

Verifiable current figures are minimal. Market-data providers show AVTI near $0.00001 per share with a market capitalization of only a few hundred dollars, consistent with an abandoned listing.

Because Avitar has not filed audited financial statements with the SEC for many years, current revenue, Earnings and balance-sheet details cannot be confirmed; some aggregators display legacy or erroneous figures that should be treated as unverified given the company's long dormancy.

What Could Come Next?

For a listing in this condition, plausible catalysts are administrative rather than clinical or commercial. A resumption of disclosure, a change of control, or a Reverse merger that repurposes the corporate shell would be developments to confirm through primary filings.

There is no announced product, regulatory submission or financing on any verifiable timeline, so the historical oral-fluid diagnostics business cannot be assumed to be active.

Risks to Watch

The risks are severe. The absence of current SEC filings for well over a decade means almost no transparency into finances, governance or whether the company operates at all. Sub-penny OTC status brings extreme illiquidity, wide spreads and a real risk of total loss.

Any future Recapitalization or reverse merger could massively dilute or displace existing holders, and promotional activity around dormant shells is a further hazard.

A Diagnostics Maker Whose Filings Ran Dry

Avitar, Inc. is a former oral-fluid diagnostics maker whose public listing has long since gone dark, leaving AVTI as a sub-penny shell with negligible market value and no verifiable recent activity.

With SEC reporting apparently halted around 2010 and no identifiable catalyst, the ticker is a distressed, speculative curiosity rather than an investable diagnostics story. Investors may want to watch EDGAR for any renewed filings or corporate action.